ByTrending Posts
How 4D Molecular Therapeutics’ Innovative Gene Therapy Engine…
Key Highlights: 1. Accelerated Clinical Milestones for 4D-150 in Wet AMD and DME: 4DMT initiated its first global…
Can BigHat and Lilly’s AI-Driven Antibody Partnership Redefine…
Key Insights AI-Driven Discovery: BigHat’s Milliner™ Platform Sets New StandardsAt the core of this collaboration is BigHat’s proprietary…
Could Proprio’s FDA-Cleared AI Platform Redefine Surgical Precision…
Key Highlights for Executives and Innovators First-Ever FDA Clearance for Real-Time Intraoperative MeasurementProprio’s Paradigm platform now holds two…
What Could Tempus and Boehringer Ingelheim’s Multi-Year AI…
Key Takeaways for Executives and Industry Leaders Tempus expands AI reach with a leading pharma partnerTempus AI, a…
What Does the Tempus–Verastem CDx Collaboration Mean for…
Key Highlights: FDA milestone: a new era for targeted LGSOC therapiesTempus AI and Verastem Oncology have joined forces…
Is the Devano and Verge Genomics AI Collaboration…
Key Executive Takeaways Transforming Drug Discovery Through AI-Driven Data IntegrationVerge Genomics, a clinical-stage biotech innovator, employs its CONVERGE®…
Can Verge Genomics’ AI-Powered VRG50635 Trial Redefine ALS…
Key Executive Takeaways Digital Biomarkers Show Disease Progression—Before Drug InterventionVerge Genomics has demonstrated that digital clinical biomarkers can…
Why Is insitro’s $25M Milestone with BMS a…
$25 Million Milestone Reached in Collaboration with Bristol Myers Squibb Unlocks First Novel ALS Target Key Highlights insitro…
Is insitro’s AI Collaboration with Moorfields Eye Hospital…
How 35 million eye scans and a new AI foundation model may redefine the future of precision medicine…
Trending Posts
Latest Stories
Can Roche’s $420 Million AI Investment in 2025 — Backed by Strategic AI Deals — Boost Discovery, R&D, and Commercial Advantage in 2026?
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and…
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial…
Can Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial…
AbbVie Invested $400 Million in AI in 2025: How This Will Transform Discovery, R&D, and Commercialization in 2026
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence…
Gallery
